Scarica l'app Stockscreener
8.02
6.08%
0.46
Dopo l'orario di chiusura:
7.64
-0.38
-4.74%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché GRFS Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$7.56
Aprire:
$7.73
Volume 24 ore:
867.57K
Relative Volume:
1.38
Capitalizzazione di mercato:
$5.46B
Reddito:
$8.51B
Utile/perdita netta:
$568.12M
Rapporto P/E:
11.90
EPS:
0.6739
Flusso di cassa netto:
$706.97M
1 W Prestazione:
+5.53%
1M Prestazione:
-11.87%
6M Prestazione:
-19.48%
1 anno Prestazione:
+12.80%
Intervallo 1D:
$7.73
$8.02
Intervallo di 1 settimana:
$7.39
$8.02
Portata 52W:
$6.19
$11.14
Grifols Sa Adr Stock (GRFS) Company Profile
Nome
Grifols Sa Adr
Settore
Industria
Telefono
-
Indirizzo
-
Compare GRFS vs LLY, JNJ, ABBV, AZN, MRK
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GRFS
Grifols Sa Adr
|
8.02 | 5.15B | 8.51B | 568.12M | 706.97M | 0.6739 |
LLY
Lilly Eli Co
|
919.77 | 792.08B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
244.44 | 584.06B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
217.49 | 376.96B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
197.22 | 300.68B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
120.29 | 291.99B | 64.93B | 18.26B | 12.36B | 7.2751 |
Grifols Sa Adr Stock (GRFS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-12 | Ripresa | Morgan Stanley | Overweight |
| 2024-03-12 | Downgrade | Deutsche Bank | Hold → Sell |
| 2023-04-12 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-03-03 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-02-16 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2023-01-18 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-04-08 | Iniziato | Morgan Stanley | Equal-Weight |
| 2021-11-05 | Downgrade | Deutsche Bank | Buy → Hold |
| 2021-10-19 | Downgrade | Barclays | Overweight → Underweight |
| 2021-10-06 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-06-14 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2021-04-20 | Iniziato | Deutsche Bank | Hold |
| 2021-03-23 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2021-03-11 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2020-10-01 | Aggiornamento | Citigroup | Sell → Neutral |
| 2020-06-09 | Downgrade | Citigroup | Neutral → Sell |
| 2020-06-09 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2020-03-25 | Downgrade | Citigroup | Buy → Neutral |
| 2019-06-27 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-02-08 | Downgrade | Berenberg | Buy → Hold |
| 2018-10-11 | Aggiornamento | Berenberg | Hold → Buy |
| 2018-06-01 | Iniziato | Barclays | Overweight |
| 2017-10-31 | Iniziato | Citigroup | Buy |
| 2017-06-30 | Downgrade | Goldman | Buy → Neutral |
| 2017-04-06 | Iniziato | BofA/Merrill | Buy |
| 2017-01-03 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2016-02-09 | Aggiornamento | Berenberg | Hold → Buy |
| 2016-01-04 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2015-12-02 | Downgrade | HSBC Securities | Buy → Hold |
| 2015-11-20 | Downgrade | Berenberg | Buy → Hold |
| 2015-04-28 | Downgrade | Berenberg | Buy → Hold |
Mostra tutto
Grifols Sa Adr Borsa (GRFS) Ultime notizie
Ban Grifols and return plasma collection to Canadian Blood Services and Héma-Québec, say health care advocates - GlobeNewswire Inc.
Grifols S.A. Stock: Navigating Debt Reduction Through US Biopharma IPO Plans Amid Market Pressures - ad-hoc-news.de
Grifols S.A. stock surges as board approves potential US IPO for biopharma unit, unlocking value in - ad-hoc-news.de
The Great Resurgence: A Deep Dive into Grifols S.A. (GRFS) in 2026 - FinancialContent
Grifols SA stock surges as board greenlights potential US IPO of plasma unit to slash debt and fuel - ad-hoc-news.de
Grifols S.A. stock surges on board approval for potential US IPO of biopharma unit - ad-hoc-news.de
Grifols: I'm Very Happy To Add In 2026 (NASDAQ:GRFS) - Seeking Alpha
Grifols FY 2025 slides: IG growth drives guidance beat despite albumin drag By Investing.com - Investing.com India
Grifols FY 2025 slides: IG growth drives guidance beat despite albumin drag - Investing.com
Earnings call transcript: Grifols Q4 2025 sees robust growth in IG franchise - Investing.com
Grifols falls 6% after skipping 2026 revenue target; €7.52 bln sales - Investing.com
ADMA Gains 13.8% in Three Months: More Upside Potential for 2026? - Finviz
Contrasting Grifols (NASDAQ:GRFS) & Sigyn Therapeutics (OTCMKTS:SIGY) - Defense World
Airbus SE – Unsponsored ADR (OTCMKTS:EADSY) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
Is Grifols S.A. the Most Slept-On Biotech Play Right Now? - ad-hoc-news.de
Revenue per share of Grifols, S.A. Sponsored ADR Class A – MUN:G0F - TradingView — Track All Markets
Grifols: Positive/Neutral Scenario Posits An Upside (NASDAQ:GRFS) - Seeking Alpha
European Index Open Up Ahead of Crucial Data Prints -- Market Talk - 富途牛牛
Price to book ratio of Grifols, S.A. Sponsored ADR Class B – BOATS:GRFS - TradingView
Validea's Top Health Care Stocks Based On Martin Zweig11/12/2025 - Nasdaq
Grifols ADR earnings matched, revenue fell short of estimates By Investing.com - Investing.com UK
Grifols slips as board rebuffs Brookfield’s $6.8B offer (update) - MSN
Grifols, S.A.American Depositary Shares (Nasdaq:GRFS) Stock Quote - FinancialContent
Validea Joseph Piotroski Strategy Daily Upgrade Report10/10/2025 - Nasdaq
Arm Holdings PLC ADRhedged (BATS:ARMH) Short Interest Down 33.3% in September - Defense World
Grifols Stock: Significant Upside Is Materializing (NASDAQ:GRFS) - Seeking Alpha
GRDLY Stock Price, Quote and News - Markets.com
Grifols Announces Interim Dividend for 2025 - The Globe and Mail
Verona Pharma, Rhythm Pharmaceuticals, AES And Other Big Stocks Moving Higher On Wednesday - Benzinga
ADMA Biologics vs. Grifols: Which Plasma Therapy Stock Is the Better Buy? - The Globe and Mail
Grifols: If This Works Out, It Has Massive Upside (NASDAQ:GRFS) - Seeking Alpha
6 undervalued stocks with low beta - Morningstar
Grifols: Looking At The Longer-Term 2025-2027 Upside After No Sale (GRFS) - Seeking Alpha
Grifols Stock Declines After Brookfield Drops Buyout Offer - Yahoo Finance
Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8% - Yahoo Finance
Spanish court opens investigation into Gotham City's attack on Grifols - Reuters
Invesco Nasdaq Biotechnology ETF Holdings - Quiver Quantitative
Grifols: Here Is Why It's Still A 'Buy' Even If Price Goes Down (NASDAQ:GRFS) - Seeking Alpha
Why Grifols (GRFS) Stock Price Moved Up 7% on Wednesday - Yahoo Finance
China Intravenous Immunoglobulin Market Size & Outlook, 2030 - Grand View Research
Europe Intravenous Immunoglobulin Market Size & Outlook, 2030 - Grand View Research
Grifols: Going Private? Brookfield On The Scene (OTCMKTS:GIFLF) - Seeking Alpha
Why Paramount Global Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket - Sahm
Grifols 2023 Annual Report on Form 20-F filed with the SEC - PR Newswire
Spanish drug maker Grifols will bring in independent directors, chairman tells newspaper - Reuters
Grifols S.A. (GRFS – ADR ADR Class B) Shares Decline Again After Gotham City Research Issues Another Critical Report – Hagens Berman - ACCESS Newswire
Grifols stock falls amid potential Moody's downgrade, new short report - Seeking Alpha
AMBAR, an Encouraging Alzheimer's Trial That Raises Questions - Frontiers
The 10 Most-Bought and Most-Sold European Stocks - Morningstar Canada
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Grifols, S.A. Investors to Inquire About Securities Class Action InvestigationGRFS, GIKLY, GIFOF, GIFLF - FinancialContent
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Grifols, S.A. Investors to Inquire About Securities Class Action Investigation – GRFS, GIKLY, GIFOF, GIFLF - Macau Business
Grifols Sa Adr Azioni (GRFS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):